Zentalis Pharmaceuticals, Inc. (ZNTL): R&D Expense
$107.30M
Year ended 2025-12-31
$116.32M
Trailing 12 months to 2026-06-30
-14.7%
3-year compound annual growth
+4.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $107.30M | -36.0% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $167.77M | -11.5% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $189.59M | +9.8% | 2026-03-26, From 2023-01-01 |
| 2022-12-31 | $172.73M | -1.6% | 2025-03-26, From 2022-01-01 |
| 2021-12-31 | $175.60M | +106.8% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $84.90M | +121.2% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $38.39M | n/a | 2022-02-24, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | 2025-12-31 | $107.30M | -36.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare ZNTL, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗